Depressive DisordersAdolescentsMajor Depressive Disorder (MDD)Ayahuasca

Acute effects of ayahuasca in a juvenile non-human primate model of depression

This animal study (n=15) investigated the efficacy of ayahuasca (0.6mg DMT, 3.1mg harmine, 0.4mg harmaline, and 0.34mg tetrahydroharmine /300g) to treat depressed marmoset monkeys exposed to 8 weeks of social isolation. They found that ayahuasca reduced scratching and depression-like behaviors, increased the feeding rate, and restored body weight and fecal cortisol to baseline levels, particularly within male monkeys.

Authors

  • Nathalia Galvão-Coelho

Published

brazilian Journal of Psychiatry
individual Study

Abstract

Objective

The incidence rate of major depression in adolescents reaches approximately 14%. This disorder is usually recurrent, without remission of symptoms even after pharmacological treatment, and persists throughout adult life. Since the effects of antidepressants take approximately 2 weeks to begin, new pharmacological therapies are under continuous exploration. Recent evidence suggests that psychedelics could produce rapid antidepressant effects. In this study, we evaluated the potential antidepressant effects of ayahuasca in a juvenile non-human primate model of depression.

Methods

While living with their families, juvenile marmosets (8 males; 7 females) were observed on alternate days for four weeks during a baseline phase. This was followed by 8 weeks of an induced depressive state protocol, the social isolated context (IC), in which the animals were monitored in the first and last weeks. Subsequently, five males and four females were randomly selected for treatment, first with a single administration of saline vehicle (1.67 mL/300 g of body weight, via gavage), followed by a single dose of ayahuasca (1.67 mL/300 g of body weight, via gavage). Both phases lasted 1 week and the animals were monitored daily. A third week of sampling was called the tardive-pharmacological effects phase. In all phases the marmosets were assessed for behavior, fecal cortisol levels, and body weight.

Results

After IC, the animals presented typical hypocortisolemia, but cortisol recovered to baseline levels 24 h after an acute dose of ayahuasca; this recovery was not observed in vehicle-treated animals. Additionally, in males, ayahuasca, but not the vehicle, reduced scratching, a stereotypic behavior, and increased feeding. Ayahuasca treatment also improved body weight to baseline levels in both sexes. The ayahuasca-induced behavioral response had long-term effects (14 days). Thus, in this translational juvenile animal model of depression, ayahuasca presented beneficial effects.

Conclusions

These results can contribute to the validation of ayahuasca as an antidepressant drug and encourage new studies on psychedelic drugs as a tool for treating mood disorders, including for adolescents with early-onset depression.

Available with Blossom Pro

Research Summary of 'Acute effects of ayahuasca in a juvenile non-human primate model of depression'

Introduction

Major depressive disorder (MDD) is a disabling condition marked by low mood, anhedonia, changes in sleep and appetite, and psychomotor disturbance. Current antidepressants target monoaminergic systems but typically require around 2 weeks to produce clinical effects and leave a substantial proportion of patients without full remission; earlier research therefore continues to seek faster-acting, more effective treatments. Ayahuasca, a traditional Amazonian decoction containing N,N-dimethyltryptamine (DMT) and b-carbolines (harmine, harmaline, tetrahydroharmine), has pharmacology relevant to depression: DMT is a 5-HT2A agonist and modulates sigma-1 receptors, while the b-carbolines act as reversible monoamine oxidase inhibitors and THH has selective serotonin reuptake inhibitory properties. Prior human and rodent studies have reported rapid neuroendocrine and antidepressant-like effects of ayahuasca, including modulation of cortisol, a hormone implicated in depression pathophysiology. Given the high incidence of adolescent-onset depression (about 14%) and the particular vulnerability of the adolescent brain during puberty, the investigators note a gap in preclinical work on ayahuasca in juvenile populations. This study therefore tested whether a single, acute administration of ayahuasca produces rapid antidepressant-like effects in a translational juvenile non-human primate model: juvenile common marmosets (Callithrix jacchus) rendered depressive-like by chronic social isolation. Outcomes included behavioural measures, fecal cortisol, and body weight, with attention to sex differences and the short-term time course (24–48 hours) and a later sampling week for tardive effects.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (5)

Papers cited by this study that are also in Blossom

Assessment of addiction severity among ritual users of ayahuasca

Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)

222 cited
Pharmacokinetics of Hoasca alkaloids in healthy humans

Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)

285 cited
Health status of ayahuasca users

Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)

420 cited

Cited By (11)

Papers in Blossom that reference this study

Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior

Galvão-Coelho, N. L., De Meiroz Grilo, M. L. P., de Sousa, G. M. et al. · Frontiers in Behavioural Neuroscience (2022)

40 cited
Ayahuasca, a psychedelic beverage, modulates neuroplasticity induced by ethanol in mice

Almeida, C. A. F., Pereira, B. P., Pereira Junior, A. A. et al. · Behavioural Brain Research (2022)

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Ruffell, S. G. D., Netzband, N., Tsang, W. et al. · Frontiers in Psychiatry (2021)

56 cited
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action

Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)

Anti-inflammatory activity of ayahuasca and its implications for the treatment of neurological and psychiatric diseases

da Silva, M. G., Daros, G. C., de Bitencourt, R. M. · Behavioural Brain Research (2021)

15 cited
The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Psychedelics as a Novel Approach to Treating Autoimmune Conditions

Thompson, C., Szabo, A. · Immunology Letters (2020)

Show all 11 papers
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial

Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.